|
Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: Additional analysis from phase IA study. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Pfizer; Pierre Fabre |
Research Funding - Millennium (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - MSD Oncology; Pfizer |
|
|
|
|
|
Honoraria - Astellas Pharma; Janssen; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Bayer; Celgene; Oncogenex; Sanofi |
Travel, Accommodations, Expenses - Bayer; Sanofi |
|
|
|
Stock and Other Ownership Interests - Caris Life Sciences |
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Endocyte; Mannkind; UpToDate |
Consulting or Advisory Role - Amgen; AVEO; BIND Biosciences; Janssen Biotech |
Speakers' Bureau - Bayer; Caris MPI; Dendreon; GlaxoSmithKline; Medivation; Millennium; Sanofi |
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Genentech/Roche |
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Genentech/Roche |
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Genentech/Roche |
|
|
No Relationships to Disclose |
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Genentech/Roche |
|
|
Consulting or Advisory Role - Genentech; Lilly; Sanofi |
Research Funding - Genentech; Lilly; Sanofi |
Travel, Accommodations, Expenses - Genentech; Sanofi |